{
  "pmcid": "11581438",
  "sha256": "2e607d5a0641f15537399ff523e01d766edda1fc541d2463a56c68d27c65c84a",
  "timestamp_utc": "2025-11-09T22:05:10.994755+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 15.612901618929019,
    "reading_ease": 18.586176836861796,
    "word_count": 219
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Repeated COVID-19 Vaccination Strategies in Kidney Transplant Recipients"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "In a multicenter, open-label, randomised controlled trial (NCT05030974), 125 KTRs were randomised"
      },
      "Participants": {
        "score": 1,
        "evidence": "125 KTRs were randomised"
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomised to receive a single dose of mRNA-1273 (100 μg, n=25), a double dose of mRNA-1273 (2×100 μg, n=25), or a single dose of Ad26.COV2.S (n=25)"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aimed to evaluate the efficacy of different repeated COVID-19 vaccination strategies in kidney transplant recipients"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the change in SARS-CoV-2-specific interleukin-21 memory T-cell and B-cell responses, measured 28 days post-vaccination."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 3,
        "evidence": "open-label"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "125 KTRs were randomised"
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "Repeated vaccination increased the seroconversion rate from 21% to 66%, significantly associated with enhanced levels of SARS-CoV-2-specific interleukin-21 memory T cells (odds ratio, 3.84 [1.89-7.78]; P<0.001) and B cells (odds ratio, 35.93 [6.94-186.04]; P<0.001)."
      },
      "Harms": {
        "score": 1,
        "evidence": "No adverse events were reported."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT05030974"
      },
      "Funding": {
        "score": 1,
        "evidence": "Supported by the Dutch Renal patients COVID-19 VACcination consortium."
      }
    },
    "total_score": 18,
    "max_score": 25
  }
}